DocWire News Editors

DocwireNews

Parsaclisib was clinically active in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who were previously treated with ibrutinib, according to results of the CITADEL-205 trial presented at the 62nd American Society of Hematology Annual Meeting &amp; Exposition.Researchers of the study, led by Pier Luigi Zinzani, MD, from the University of Bologna in Italy, assessed the objective response rate (ORR) associated with parsaclisib in adult patients with R/R MCL. Patients in this study had received a median of three prior systemic therapies, including ibrutinib.The investigators assigned patients to once-daily parsaclisib 20 mg for eight weeks followed by either once-weekly 20 mg or once-daily 2.5 mg. Additionally, the researchers initiated prophylaxis for pneumocystis jirovecii pneumonia.A total of 47 patients were treated in the study, but 70% of patients discontinued at time of data cutoff. Treatment discontinuation was primary due to progressive disease (62%). The median treatment exposure was 2.2 months, and the median age was 70 years. Most patients were men (79%) and had an Eastern Cooperative Oncology Group performance status score of 1 or more (85%).After the median follow-up period of 10.2 months, the ORR in 46 patients evaluable for efficacy was 28.3% (95% confidence interval [CI], 16.0-43.5), whereas the complete response rate was 2.2%. Additionally, the median duration of response was 7.3 months (95% CI, 0.2 to not estimable) in responders. Overall, the median time to a complete or partial response was 7.6 weeks.Also, the investigators found that the median overall progression-free survival in this population was 3.65 months (95% CI, 1.9-3.9).The most common treatment-emergent adverse events (AEs) in the 47 safety-evaluable patients were anemia (19.1%), diarrhea (19.1%), neutropenia (14.9%), asthenia (12.8%), cough (12.8%), decreased appetite (10.6%), dyspnea (10.6%), fatigue (10.6%), pyrexia and rash (10.6%).Serious treatment-related AEs that occurred in two or more patients included diarrhea, dyspnea, peripheral swelling, and pneumonia (4.3% each).

Jordana Jampel

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Latest News

Parsaclisib Leads to Clinically Meaningful Activity in R/R MCL Previously Treated with Ibrutinib

ASH Annual Meeting 2020

Parsaclisib was clinically active in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who were previously treated with ibrutinib, according to results of the ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe